Skip to main content

Table 3 Selected neuropsychiatric adverse events (NP-AEs) after the use of dolutegravir (DTG) among the uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) genotypes

From: Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1

 

−/−

−/*28

−/*6

*28/*28

*6/*28

*6/*6

n = 51

n = 18

n = 23

n = 3

n = 4

n = 8

Insomnia (n)

4

4

2

1

1

2

Headache (n)

2

2

3

1

0

1

Dizziness (n)

5

3

0

0

1

0

Restlessness (n)

2

0

1

0

1

0

Anxiety (n)

0

0

1

0

1

0

At least one NP-AEs (n, %)

11 (22%)

8 (44%)

7 (30%)

2 (67%)

3 (75%)

3 (38%)